MiMedx Group, Inc (MDXG)

Price$3.74

Value ScoreA

Growth ScoreC

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-53.56%

Price vs S&P 500 (4W)3.90%

VGM Score53.83

Market Capitalization$557.06M

P/E Ratio (Annual)11.47x

All Metrics

P/CF (Annual)7.53x

Book Value / Share (Quarterly)$1.63

P/TBV (Annual)4.14x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)16.06%

Cash Flow / Share (Quarterly)$0.47

Price vs S&P 500 (YTD)-52.91%

Gross Margin (TTM)81.04%

Net Profit Margin (TTM)7.88%

EPS (TTM)$0.20

10-Day Avg Trading Volume1.46M

EPS Excl Extra (TTM)$0.20

Revenue Growth (5Y)11.02%

EPS (Annual)$0.32

ROI (Annual)17.70%

Gross Margin (Annual)82.56%

Net Profit Margin (5Y Avg)5.32%

Cash / Share (Quarterly)$1.07

P/E Basic Excl Extra (TTM)18.15x

Revenue Growth QoQ (YoY)-33.12%

P/E Normalized (Annual)11.47x

ROA (Last FY)14.18%

Revenue Growth TTM (YoY)10.51%

EBITD / Share (TTM)$0.27

ROE (5Y Avg)6.01%

Operating Margin (TTM)10.17%

Cash Flow / Share (Annual)$0.49

P/B Ratio2.29x

P/B Ratio (Quarterly)2.42x

Net Income / Employee (Annual)$60,100

EV / Revenue (TTM)1.07x

Net Interest Coverage (TTM)77.70x

ROA (TTM)9.73%

EPS Growth QoQ (YoY)103.21%

EV / EBITDA (TTM)10.31x

EPS Incl Extra (Annual)$0.32

Current Ratio (Annual)4.32x

Quick Ratio (Quarterly)4.81x

3-Month Avg Trading Volume1.34M

52-Week Price Return-41.01%

EV / Free Cash Flow (Annual)5.69x

P/E Incl Extra (TTM)18.15x

Revenue / Employee (TTM)$482,000

Tangible BV / Share (Quarterly)$1.39

P/S Ratio (Annual)1.33x

Asset Turnover (Annual)1.22x

52-Week High$7.99

Operating Margin (5Y Avg)6.48%

EPS Excl Extra (Annual)$0.32

CapEx CAGR (5Y)-25.69%

Tangible BV CAGR (5Y)23.20%

26-Week Price Return-45.64%

Quick Ratio (Annual)3.92x

13-Week Price Return-21.26%

Total Debt / Equity (Annual)0.07x

Current Ratio (Quarterly)5.39x

Enterprise Value$414.88M

Revenue / Share Growth (5Y)4.06%

Asset Turnover (TTM)1.23x

Book Value / Share Growth (5Y)16.02%

Revenue / Employee (Annual)$518,100

Inventory Turnover (Annual)2.97x

Pretax Margin (Annual)15.83%

Cash / Share (Annual)$1.12

3-Month Return Std Dev51.35%

Gross Margin (5Y Avg)82.71%

Net Income / Employee (TTM)$38,000

ROE (Last FY)18.94%

Net Interest Coverage (Annual)8.59x

EPS Basic Excl Extra (Annual)$0.32

P/FCF (TTM)8.04x

Receivables Turnover (TTM)7.19x

EV / Free Cash Flow (TTM)5.99x

Total Debt / Equity (Quarterly)0.07x

EPS Incl Extra (TTM)$0.20

Receivables Turnover (Annual)6.37x

ROI (TTM)11.95%

P/S Ratio (TTM)1.43x

Pretax Margin (5Y Avg)5.34%

Revenue / Share (Annual)$2.80

Tangible BV / Share (Annual)$1.64

Forward P/E32.53x

Price vs S&P 500 (52W)-65.38%

P/E Ratio (TTM)18.15x

EPS Growth TTM (YoY)-24.25%

Year-to-Date Return-44.76%

5-Day Price Return4.47%

EPS Normalized (Annual)$0.32

ROA (5Y Avg)6.30%

Net Profit Margin (Annual)11.60%

Month-to-Date Return1.63%

Cash Flow / Share (TTM)$0.01

EBITD / Share (Annual)$0.44

Operating Margin (Annual)15.26%

LT Debt / Equity (Annual)0.06x

P/CF (TTM)7.89x

ROI (5Y Avg)7.24%

P/E Excl Extra (TTM)18.15x

LT Debt / Equity (Quarterly)0.07x

EPS Basic Excl Extra (TTM)$0.20

P/TBV (Quarterly)2.83x

P/B Ratio (Annual)3.91x

Inventory Turnover (TTM)2.94x

Pretax Margin (TTM)10.87%

Book Value / Share (Annual)$1.73

Price vs S&P 500 (13W)-29.52%

Beta1.50x

P/FCF (Annual)7.63x

Revenue / Share (TTM)$2.62

ROE (TTM)12.86%

52-Week Low$3.03

vGradeA

gGradeC

mGradeD

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.05est. -0.03

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.08

Industry Peers — Surgical & Medical Instruments(138)

Symbol	Value Score	Growth Score	Momentum Score	Price
MDXGMiMedx Group, Inc	A	C	D	$3.74
SYKStryker Corporation	C	C	C	$305.66
MMM3M Company	C	F	C	$153.76
BSXBoston Scientific Corp.	C	B	D	$48.55
MDLNMedline Inc. Class A common stock	C	D	D	$33.61
BDXBecton, Dickinson and Co.	B	C	C	$151.16
RMDResMed Inc.	C	B	C	$196.04
DXCMDexCom, Inc.	C	B	C	$72.86
WSTWest Pharmaceutical Services, Inc.	D	C	B	$314.50
SOLVSolventum Corporation	C	D	B	$81.01
PENPenumbra, Inc.	F	C	B	$320.53

About

MiMedx Group develops regenerative biomaterial products derived from human amniotic membrane and birth tissues for wound care, surgical, burn, orthopedic, and sports medicine applications. The company's core offerings include EpiFix and AmnioFix, flagship allografts that address external and internal wound healing needs across multiple surgical specialties. MiMedx also generates revenue through licensed partnerships for ophthalmic and dental applications.